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New pyrazolyl-diamine ligands with acridine derivatives at the 4-position of the pyrazolyl ring were
synthesized and characterized (L1 and L2). Coordination towards the fac-[M(CO)3]+ (M = Re, 99mTc)
led to complexes fac-[M(CO)3(k3-L)] (L = L1: M = Re1, Tc1; L = L2: M = Re2, Tc2). The interaction of
the novel pyrazolyl-diamine ligands (L1 and L2) and rhenium(I) complexes (Re1 and Re2) with calf
thymus DNA (CT-DNA) was investigated by a variety of techniques, namely UV-visible, ﬂuorescence
spectroscopy and circular and linear dichroism. Compounds L1 and Re1 have moderate afﬁnity to
CT-DNA and bind to DNA by intercalation, while L2 and Re2 have a poor afﬁnity for
CT-DNA. Moreover, LD measurements showed that L1 and Re1 act as perfect intercalators. By
confocal ﬂuorescence microscopy we found that L1 and Re1 internalize and localize in the nucleus of
B16F1 murine melanoma cells. The congener Tc1 complex also targets the cell nucleus exhibiting a
time-dependent cellular uptake and a fast and high nuclear internalization (67.2% of activity after 30
min). Plasmid DNA studies have shown that Tc1 converts supercoiled (sc) puc19 DNA to the open
circular (oc) form.
Introduction
Treatment of cancer still remains a great challenge for modern
medicine, in particular the eradication of disseminated tumor
cells and small metastases which cannot be treated efﬁciently with
external radiation therapy or surgery. More recently, radionuclide
therapy started to be envisaged as an alternative and powerful
modality for the treatment of disseminated malignant diseases.1
So far, clinical radionuclide therapy relies on the use of b- emitter
(e.g. 131I, 90Y) radiopharmaceuticals which are mainly applied
for bone pain palliation and for treatment of neuroendocrine
or hematological tumors.2 However, b- emitters are not the
best suited radionuclides to eliminate disseminated cells or small
metastases, since most of the energy of b- particles is absorbed
by the surroundings and not by the target neoplastic cells
which accumulate the radiopharmaceutical. For such type of
application, a- and Auger electron emitters can be considered a
more adequate choice than traditional b- emitters, but the studies
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with these radionuclides remain mostly pre-clinical. Nevertheless,
Auger radiation therapy appears to be a new possible therapeutic
pathway with in vitro experimental results already demonstrated
for 125I, 111In and 99mTc.3–8
99mTc, themost used g-emitter in SPECT (single photon emission
computed tomography) imaging, emits also 4 Auger electrons per
decay. These low energy electrons provide a high linear energy
transfer (high LET) in association with a short tissue penetration,
being therefore optimal for treatment of individual cancer cells.
However, such application requires a selective accumulation of
the radionuclide into individual tumor cells, namely in the
nucleus, being highly toxic only when the Auger emitter is
tightly bound to DNA.1 To ensure the close proximity of the
emitting radionuclide to the DNA double helix and a prolonged
retention time in the cell it is imperative to design multifunctional
compounds bearing a DNA-binding unit.3,9 For 99mTc, Alberto
et al. pioneered the study of such type of compounds and
demonstrated in vitro that the Auger electrons emitted by 99mTc
strongly affect the structure of plasmid DNA with induction of
double strand breaks.8 In our research group, we have also studied
and evaluated Re(I)/99mTc(I) tricarbonyl complexes anchored by
pyrazolyl-diamine chelators and bearing anthracenyl groups for
DNA binding.10–12 Our ﬁndings were encouraging since some of
the anthracenyl-containing 99mTc(I) tricarbonyl complexes rapidly
entered the cells, accumulated inside the nucleus and exhibited
a strong radiotoxic effect in murine melanoma cells with an
apoptotic cellular outcome. However, the evaluated complexes
only presented a moderate afﬁnity to DNA and did not behave
as perfect intercalators. Moreover, the anthracene chromophore
did not display the best emission properties to allow the follow-
up of the cellular trafﬁcking of the Re congeners by ﬂuores-
cence microscopy. To get a deeper insight into the relevance of
pyrazolyl-diamine 99mTc(I) tricarbonyl complexes in the design of
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Scheme 1 Synthesis of chelators L1 and L2.
site-directed radiopharmaceuticals for Auger therapy we decided
to explore their functionalization with acridine derivatives which
are another family of known DNA-binding molecules. By ex-
ploring acridine derivatives, we intended to obtain organometallic
complexes with a higher DNA-binding afﬁnity and with a better
ability to intercalate into the double helix compared with the
complexes bearing anthracenyl groups previously evaluated.10–12 In
addition, acridine derivatives are polyaromatic ﬂuorescent planar
molecules considered as standard compounds for nuclear staining
due to their strong emission properties. Therefore, the use of such
chromophores should also allow an easier visualization of the
cellular trafﬁcking of the compounds by confocal ﬂuorescence
microscopy.
Herein, we report on the synthesis and characterization of
new multifunctional pyrazolyl-diamine ligands bearing DNA-
binding motifs of the acridine type, which have been attached
at the 4-position of the azolyl ring using appropriate methylenic
linkers. The synthesis, characterization and in vitro evaluation of
the respective Re(I)/99mTc(I) tricarbonyl complexes will be also
presented. This includes the study of the interactionwithCT-DNA
by a variety of spectroscopic techniques, ﬂuorescence microscopy
studies, intracellular distribution studies and evaluation of damage
in plasmid DNA.
Results and discussion
Synthesis of pyrazolyl containing chelators bearing acridine
derivatives and respective metal complexes
Twopyrazolyl diamine chelators bearing acridine derivatives at the
4-position of the pyrazolyl ring (L1 and L2) were synthesized as
depicted in Scheme 1. A ﬁrst step consisted of the synthesis of 10-
(4-amino-butyl)-3,6-bis-dimethylamino-acridinium (1) and N-(4-
aminobuthyl)acridine-9-carboxamide (2), prepared respectively,
from the commercially available acridine orange and 9-acridine
carboxylic acid and following described methodologies.13 Then,
chromophores 1 and 2 were conjugated to the protected and
activated pyrazolyl-diamine derivative 3, recently synthesized and
characterized in our group.14 Such conjugation was successfully
done in dry DMF, in the presence of DIPEA, at room temperature
and after ﬁve days of reaction. After appropriate work-up,
compounds 4 and 5 were obtained as a dark orange and yellow
oil, respectively. The Boc protecting group was then removed
by overnight reaction of 4 and 5 with TFA in CH2Cl2, at
room temperature. The unprotected conjugates were dried under
reduced pressure and the crude puriﬁed by washing with ethyl
acetate (L1) or with CH2Cl2 followed by column chromatography
puriﬁcation (L2). Compounds L1 and L2 were then obtained as
This journal is © The Royal Society of Chemistry 2010 Org. Biomol. Chem., 2010, 8, 4104–4116 | 4105
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a red-orange solid (83% yield) or as a yellow oil (84% yield),
respectively.
The new compoundsL1–L2were characterized bymultinuclear
NMR spectroscopy (1H, 13C and 18F), ESI-MS, elemental analysis
and HPLC. In the 1H NMR spectra of L1 and L2 the resonances
due to the acridine unitswere easily identiﬁed between 6.5–8.6 ppm
for L1 and 7.5–8.1 ppm for L2, while the methylenic protons of
the diamine framework appear between 3 and 4.3 ppm for L1
and between 2.6 and 4.0 ppm for L2. For both compounds, two
resonances, integrating for three protons each, appear for the 3,5-
Me2 groups of the pyrazolyl ring (at approx. 2 ppm), while the
methylenic protons at the 4-position of the same ring appear at
about 3.2 ppm. The butylenic protons of the linker between the
pyrazolyl diamine framework and the acridine units appear at
1.82 (2H), 1.98 (2H), 3.23 (2H, overlapping with Me groups of the
chromophore), and 4.70 (2H) ppm for L1 and at 1.70 (4H), 2.16
(2H) and 3.61 (2H) ppm for L2. In the 13C NMR spectra all the
expected resonances could be identiﬁed, including the ones due to
the TFA.ByHPLCone single peakwas found for each compound,
with retention times of 14.99 min and 10.95 min for L1 and L2,
respectively. In the positive mode, the ESI-MS spectra showed
prominent peaks at m/z values corresponding to the expected
molecular ions: [M]+ = 559.1 for L1 and [M + H]+ = 516.1 for L2.
Reactions of fac-[Re(H2O)3(CO)3]BrwithL1 andL2 in reﬂuxing
methanol, followed by column chromatography puriﬁcation, led
to the cationic tricarbonyl complexes Re1 and Re2 (Scheme 2).
Complexes Re1 and Re2 are red-orange and yellow solids,
respectively. They are stable towards air oxidation or hydrolysis
and are soluble in water and MeOH. Their characterization
was based on IR and multinuclear NMR spectroscopy, ESI-MS,
elemental analysis and HPLC. The IR spectra showed intense
absorption bands in the range 1890–2024 cm-1, easily assigned to
the n (C O) stretching modes of the fac-[Re(CO)3]+ unit. These
frequencies compare well with the values found for other Re(I)
tricarbonyl complexes anchored by pyrazolyl-diamine chelators
of the same family.15 The 1H NMR data obtained for Re1 and
Re2 indicate that L1 and L2 coordinate to the metal through the
pyrazolyl-diamine framework, in a tridentate coordination mode.
Such assignment was based mainly on the chemical shift and
splitting of the two -NH2 protons which become diastereotopic
after coordination to the metal (3.86 ppm and 5.41 ppm for
Re1; 3.90 ppm and 5.39 ppm for Re2) and methylenic protons
Table 1 Labelling conditions, HPLC retention time and log Po/w values
for Tc1 and Tc2
Complex t/min T/◦C tR/mina log P0/w ± SD
Tc1 40 100 17.92 (17.69) 0.56 ± 0.02
Tc2 30 100 16.17 (15.06) 0.74 ± 0.01
a The retention time for the Re complexes are in parenthesis
of the pyrazolyl-diamine unit which also become diastereotopic
originating eight resonances, integrating for one proton each,
in the range 2.40 ppm and 4.60 ppm. The pattern obtained is
comparable to the one found for other complexes stabilized with
chelators of the same family. In Re1 and Re2 the resonances
from the pyrazolyl-diamine framework exhibit chemical shifts
signiﬁcantly different from those of the corresponding protons
in the respective free ligands. In contrast, the signals due to the
protons of the chromophoric units, as well as those due to the
methylenic and butylenic linkers between the chromophores and
the pyrazolyl-diamine backbone, present a splitting and chemical
shifts very similar to those of the free ligands, conﬁrming that
the chromophore units don’t interact with the metal center. In
the positive mode, prominent peaks with the expected isotopic
pattern could be found in the ESI-MS spectra of Re1 and Re2 at
m/z 414.9 ([M]2+) and 786.0 ([M]+), respectively. The synthesis of
the 99mTc complexes (Tc1 and Tc2) was done in aqueous solution
by reaction of fac-[99mTc(H2O)3(CO)3]+ with the appropriate ligand
(L1 orL2) at 100 ◦C for 30 to 40min and pH 7.4 (Scheme 2). These
complexes were obtained in almost quantitative yield (> 98%)
using a relatively low ﬁnal concentration of ligand (10-4 M). The
chemical identity of Tc1 and Tc2 was ascertained by comparison
of their HPLC proﬁles with those of the corresponding rhenium
complexes (Re1–Re2). The respective retention times are presented
in Table 1. These radiocomplexes are stable under physiological
conditions, including in the cell culture media (data not shown).
The lipophilicity of complexes Tc1 and Tc2 was assessed by
measurement of the respective log Po/w values (n-octanol/0.1 M
PBS, pH 7.4) using the multiple back extraction method.16 The
complexes Tc1 and Tc2 exhibited a hydrophobic character with
log Po/w values of 0.56 ± 0.02 and 0.74 ± 0.01, respectively
(Table 1).
Scheme 2 Synthesis of the Re and 99mTc complexes.
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Fig. 1 Absorption spectra of L1 (4.25 ¥ 10-5 M) and Re1 (1.5 ¥ 10-5 M) in the presence of increasing amounts of CT-DNA (0.02, 0.04, 0.06, 0.08, 0.13,
0.17, 0.23 and 0.33 mM for L1; 0.01, 0.02, 0.04, 0.05, 0.07, 0.10, 0.14, 0.21 and 0.40 mM for Re1) in Tris-HCl 0.1M buffer.
DNA-binding studies
The interaction of L1, L2, Re1 and Re2 with CT-DNA was
evaluated by UV-visible, ﬂuorescence, CD and LD spectroscopies.
These studies consisted of monitoring the changes of the bands
due to the acridine chromophores upon addition of increasing
amounts of DNA.
UV-visible spectroscopy
From the UV-visible titration of compounds L1 and Re1 (Fig. 1)
it was observed that the absorption peak of the free compounds
present amaximumat 496 nm,which is red shifted uponbinding of
DNA (maximum at 506 nm). Additionally, the shoulder observed
at 470 nm changed to 480 nm after interaction of the species with
the DNA double helix. This red shift (Dl = 10 nm) is in agreement
with the results reported by other authors for acridine orange (AO)
and for a Pt(II) complex bearing a pendant AO fragment, and is
consistent with an intercalative binding of the compounds.17–19
As the DNA concentration increases, the shoulder at 470 nm
diminishes in intensity. Such a shoulder can be assigned to the
presence of dimeric species, resulting from the self-association of
AOrings, their formation being less probablewhen the compounds
bind to DNA. The shape and intensity of the band at 506 nm due
to the bound compounds remained fairly constant, indicating that
L1 and Re1 act most probably as intercalated monomers without
any interaction between themselves.
TheUV-vis spectra ofL2 andRe2 (see Fig. S1 in Supplementary
Information) show an absorption maximum at 359 nm. Upon
addition of CT-DNA, there is a moderate hypochromicity but
no bathochromic shift is observed. These ﬁndings indicate that
these compounds have a low propensity to interact with DNA by
intercalation.
Fluorescence spectroscopy
The addition ofDNA to solutions ofL1 andRe1 led to the increase
of the emission intensity until a saturation value was reached
(Fig. 2). Such enhancement of ﬂuorescence clearly indicates the
intercalation of the AO moiety of compounds L1 and Re1 into the
DNA double helix, as claimed by other authors for different AO
derivatives.13,17
Fig. 2 Fluorescence spectra of L1 (1.06 ¥ 10-5 M, left) and Re1 (1.5 ¥ 10-6 M, right) in the presence of increasing amounts of CT-DNA (5.6, 8.4, 11.1,
13.9, 16.6, 21.5, 26.4, 36.0, 50.1 and 59.3 mM for L1; 4.0, 7.8, 11.7, 15.5, 19.3, 23.1, 30.1, 37.0, 50.6, 70.4 and 83.2 mM for Re1) in Tris-HCL 0.1M buffer.
Excitation at 470 nm.
This journal is © The Royal Society of Chemistry 2010 Org. Biomol. Chem., 2010, 8, 4104–4116 | 4107
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Fig. 3 ICD spectra of compounds L1 (left) and Re1 (right) at several ratios of [DNA]/[probe] concentrations for a CT-DNA concentration of 2.5 ¥
10-5 M nucl-1: A) 0.2 eq. of probe; B) 2 eq. of probe.
For L2 and Re2, the addition of DNA induces a quenching of
the ﬂuorescence (Fig. S2, S. I.), as commonly found for acridine
derivatives due to an energetically favorable electron-transfer
reaction from the DNA bases to the acridine moiety.20 However,
only a slight ﬂuorescence quenching was observed, particularly
in the case of Re2. This certainly reﬂects the low afﬁnity of
these compounds to DNA, as already indicated by the UV-vis
experiments.
Induced circular (CD) and linear dichroism (LD)
The compounds L1, Re1 and L2, Re2 do not present CD spectra,
in agreement with the expected non-chirality of the molecules.
However, their association with the right-handed DNA helix
should led to ICD spectra in the range where the acridine or
AO chromophores absorb (400–525 nm). From the compounds
studied, onlyL1 andRe1 showpositive ICDspectra in the expected
spectral range (Fig. 3), as a result of the close proximity between
the chromophores and the biomolecule. For 0.2 equivalents of
DNA we have observed one positive band at 516 nm and two
negative bands at 475 nm and 489 nm with intensities varying
greatlywith increasing amounts of the chromophores. These bands
can be assigned to intercalated compounds by comparison with
the ICD spectra reported previously for AO bound to DNA.17
For compounds L2 and Re2 it was not possible to register any
changes in the CD spectra of the species in the presence of CT-
DNA, showing once again the poor interaction ability of these
compounds with the biomolecule.
LD studies were performed in order to get better information
about the spatial orientation of the chromophore relative to the
DNA double helix. Both L1 and Re1 induced a strong increase in
the signal intensity for theDNAband (230–300nm) indicating that
the DNA becomes more oriented within the hydrodynamic ﬁeld
upon interaction because of stiffening of the helix on intercalation
of these compounds (Fig. 4). Furthermore, a negative signal
also emerged in the chromophore region (400–525 nm) which
suggests an intercalation bindingmode forL1 andRe1. The nearly
constant value of LDr in this spectral range conﬁrms the perfect
intercalation for both species.
Table 2 Intrinsic binding constants (K) for L1 and Re1
K/M-1 ¥ 105
Spectroscopic technique Model L1 Re1
UV-Visible Scatchard 1.71 ± 0.01 2.50 ± 0.01
Kaminoh 1.75 ± 0.15 2.33 ± 0.39
Fluorescence Scatchard 1.53 ± 0.01 2.26 ± 0.01
Kaminoh 1.93 ± 0.22 2.36 ± 0.02
McGhee von Hippel 1.93 ± 0.86 1.17 ± 0.68
n = 2.7 n = 17.8
For compounds L2 and Re2, the addition of DNA also led to
the appearance of a negative band in the chromophore absorption
region (300–400 nm) (Fig. S3, S.I.). However, even for the highest
concentrations of DNA, its intensity was much lower than the
intensity of the bands induced by L1 and Re1. Therefore, the LD
studies conﬁrmed once again that compounds L2 and Re2 have a
lower afﬁnity towards the DNA double helix in comparison with
L1 and Re1. The presence of these negative bands suggests that L2
and Re2 can intercalate into the DNA double helix. However, the
LDr signal in this spectral range is largely wavelength dependent
and its intensity is higher than that of DNA alone, indicating that
these compounds are only partially intercalated.
DNA binding constant
The data obtained for compounds L1 and Re1 in the UV-visible
and ﬂuorescence titrations were used to obtain the intrinsic
binding constants (K) (Table 2) by adjustment to different math-
ematical and computational models (see Experimental Section).
Simple Scatchard and Kaminoh models were ﬁtted to the UV-
vis and ﬂuorescence data; the ﬂuorescence data were also ﬁtted
to the non-cooperative McGhee von Hippel model. As discussed
above, compoundsL2 andRe2 revealed a poor interactionwith the
DNA and no model could be adjusted to determine the respective
binding constants.
For L1, the adjustment of the McGhee von Hippel model gave
a K value of (1.93 ± 0.86) ¥ 105 M and a binding size site (n) of
4108 | Org. Biomol. Chem., 2010, 8, 4104–4116 This journal is © The Royal Society of Chemistry 2010
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Fig. 4 Linear dichroism (LD, upper panels) and reduced linear dichroism (LDr, lower panels) of L1 (left) and Re1 (right) at different [DNA]/[probe]
molar ratios: A) no probe; B) 25; C) 12; D) 5. Spectra were recorded in 10 mM phosphate buffer at pH 7.2.
2.7. These values are comparable with those reported for acridine
orange, particularly inwhich concerns the n value that is consistent
with an intercalative binding of the molecule.21–23 By contrast, a
large n value (17.8)was determined forRe1which indicates that the
obtained data are not consistent with a nearest neighbor exclusion
intercalation model. This might result from the involvement of
different binding modes in the range of concentrations needed
to reach saturation in the case of Re1.24 In fact, L1 reached
saturation at 59.3 mM of CT-DNA whereas Re1 required 83.2 mM
of CT-DNA to reach saturation. Complex Re1 has a larger net
positive charge (+2) that may favor electrostatic interactions with
the phosphate groups from the outer-part of the DNA double
helix, justifying the highest DNA concentration needed to reach
saturation.
As discussed above, the McGhee von Hippel model was not
properly ﬁtted to ﬂuorescent data obtained for the DNA titration
of Re1. Therefore, the binding constant calculated based on
such adjustment should be considered with caution. In order to
compare the DNA afﬁnity of L1 and Re1, the respective binding
constants (K) were determined using Scatchard and Kaminoh
models, based on the UV-vis and ﬂuorescence data. Based on
these models, the K values determined for Re1, spanning between
(2.26 ± 0.01) ¥ 105 and (2.50 ± 0.01) ¥ 105 M-1, were consistently
higher than those found for L1 ((1.53 ± 0.01) ¥ 105–(1.93 ± 0.22) ¥
105 M-1). This certainly reﬂects the higher positive charge of Re1
that may favor electrostatic interactions with the DNA phosphate
groups.
Cellular and nuclear uptake studies
When designing a 99mTc-radiopharmaceutical, namely as a poten-
tial candidate for Auger electron therapy, it is very important to
quantify the cellular and nuclear uptake of the compounds but is
also important to follow the trafﬁcking of the compounds at cellu-
lar and subcellular level, in real time. The cell uptake quantiﬁcation
can be easily done using the radioactive 99mTc-complexes, but the
trafﬁcking can only be evaluated using analogous and ﬂuorescent
Re complexes.
Taking advantage of the ﬂuorescence emission characteristics of
the chromophore units of the newly synthesized compounds, the
cellular uptake for the ligands L1 and L2 and the corresponding
complexes, Re1 and Re2, was assessed by ﬂuorescence microscopy
in B16F1 murine melanoma cells. Compounds L1 and Re1 were
detected by the emission of green ﬂuorescence and the nuclear
localization was evaluated by comparison with the nuclear stain
DAPI. Compounds L2 and Re2 were detected by the emission of
blue ﬂuorescence and the nuclear localization was evaluated by
comparison with the nuclear stain DRAQ5.
L1 and Re1 were detected in the cytoplasm and in the nucleus,
speciﬁcally in the nucleoli (data not shown). L2 and Re2 also
localize in the cytoplasm and in the nucleus of the cells but
present a less intense emission of ﬂuorescence. This lower emission
intensity led to a lower deﬁnition of the images, due to the longer
exposure time required for the capture (data not shown). Due to
the promising results obtained for L1 and Re1 the cellular uptake
of these compounds was further evaluated by confocal laser-
scanning ﬂuorescence microscopy, which conﬁrmed the cellular
localization of L1 and Re1 in the cytoplasm and nucleus in
association with the nucleoli (Fig. 5).
To quantify the cellular and nuclear internalization found for
Re1 using ﬂuorescence microscopy, we have studied the behavior
of Tc1 with the same cell line. These studies were performed
using B16F1 murine melanoma cells and the HPLC puriﬁed Tc1
complex.
The cellular internalization of Tc1 was performed at 37 ◦C and
was time-dependent (Fig. 6). Moderate levels of internalization
This journal is © The Royal Society of Chemistry 2010 Org. Biomol. Chem., 2010, 8, 4104–4116 | 4109
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Fig. 5 Uptake of compounds L1 and Re1 (70 mM) by B16F1 murine
melanoma cells evaluated by confocal ﬂuorescence microscopy (blue:
nuclei; white arrows: nucleoli).
were reached. For example, at 5 h post-incubation a value
of 7.8% was obtained, when internalization is expressed as a
percentage of total activity (Fig. 6A). For the same time of
incubation, approximately 34% of the bound activity (activity on
the membrane and inside the cell) was taken up and internalized
by the cells (Fig. 6B).
The cellular retention of Tc1 was evaluated at different time
points, after 3 h of internalization (Fig. 7). The radiocomplex was
slowly released from the cells into the culture medium, with about
60% of the initially internalized complex still remaining inside the
cells at 3 h post-incubation.
Nuclear internalization of compound Tc1 in B16F1 cells was
also determined. The percentage of activity internalized into the
nucleus per total activity is presented in Fig. 8A. At 6 h post-
incubation, 3.8% of the administered compound was internalized
into the cell nucleus.
The nuclear internalization was also determined by the ratio
between the activities internalized into the nucleus and the cell-
bound activity (Fig. 8B). Such calculation gives a more accurate
measure of the ability of the complex to pass from the cytoplasm to
the nucleus. As can be seen in Fig. 8B, the nuclear internalization
is very fast and the percentage of compound inside the nucleus
is higher than that outside (i.e., cytoplasm and cell membrane).
After 30 min, 67.2% of Tc1 was found in the nucleus. This shows
that the radioactive compound rapidly diffuses to the cell nucleus
after being internalized by the cell, reﬂecting most probably its
afﬁnity to DNA.
Fig. 7 Cellular retention of the internalized complex Tc1 in B16F1 cells
over time at 37 ◦C (mean ± standard deviation, n = 3).
Plasmid DNA studies
Since Re1 was shown to interact strongly with CT-DNA and the
congener Tc1 presented an enhanced ability to target the nucleus,
we decided to evaluate if the Auger electrons emitted by 99mTc
would induce damage on plasmidDNA, upon formation of single-
strand breaks (SSB) or double-strand breaks (DSB). These studies
were also performed for the congener Re1 and for [99mTcO4]-, in
order to check if the eventual damage is due to the radioactive
character of Tc1 combined with its ability to intercalate into
the DNA double helix. The non-radioactive Re1 was evaluated
in a 10-8 M concentration, corresponding approximately to the
molar concentration used for Tc1. Tc1 and [99mTcO4]- were studied
using the same amount of radioactivity (150–310 mCi). Samples
of [99mTcO4]- and complexes Re1 and Tc1 were incubated with
plasmid DNA (puc19) and the formation of strand breaks was
analyzed by agarose gel electrophoresis. As can be seen in Fig. 9,
Tc1 (C and D) induced a more pronounced reduction of the
supercoiled (sc) band intensity compared with complex Re1 (G)
and with [99mTcO4]- (E and F). The total plasmid DNA containing
strand breaks corresponded to more than 30% in the case of Tc1,
roughly to 15% for Re1 and to less than 6% for [99mTcO4]-. For
all the compounds, the damaged DNA is uniquely in the open
Fig. 6 Cellular internalization of Tc1 at 37 ◦C in B16F1 murine melanoma cells. A) Internalization expressed as a percentage of total activity; B)
internalized and surface bound activity expressed as a fraction of cell-bound activity (mean ± standard deviation, n = 3).
4110 | Org. Biomol. Chem., 2010, 8, 4104–4116 This journal is © The Royal Society of Chemistry 2010
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Fig. 8 Nuclear internalization of Tc1 at 37 ◦C in B16F1 murine melanoma cells. A) Nuclear internalization expressed by total activity; B) activity inside
the nucleus and outside the nucleus expressed as a percentage of cell-bound activity (mean ± standard deviation, n = 3).
Fig. 9 Cleavage of supercoiled (sc) puc19 DNA, after 48 h of incubation
at room temperature in Tris (pH 7.4): A – molecular weight marker – 1 Kb
DNA ladder; B – control (DNA + buffer); C – DNA + Tc1, 310 mCi; D
– DNA + Tc1, 150 mCi; E – DNA + [99mTcO4]-, 310 mCi; F – DNA +
[99mTcO4]-, 150 mCi; G – DNA + Re1 (10-8 M).
circular (oc) form, no linear form being detected. In summary,
complex Tc1 induces more easily SSB in plasmid DNA compared
with Re1 and with [99mTcO4]-. This probably reﬂects the expected
high afﬁnity of Tc1 to DNA and its ability to act as a perfect
intercalator, taking into consideration the interaction studies with
DNA performed for the isostructural Re1. However, Tc1 was
unable to provoke DSBs as would be expected if the emission
of Auger electrons by the 99mTc radionuclide could occur in a
close proximity to DNA. For 125I-labelled molecules, it has been
reported in several instances that small changes in the position
of the decay site may have strong effects on the yields of SSBs
and DSBs.4 Eventually, the butylenic linker used to attach the AO
fragment to the planar azolyl ring allows a perfect intercalation
of the chromophore but is too long to assure the proximity of the
radiometal to the DNA bases, necessary to have DSBs induced by
the emitted Auger electrons.
Concluding remarks
Novel pyrazolyl-diamine chelators bearing acridine derivatives at
the 4-position of the pyrazolyl ring have been synthesized and
characterized (L1, L2) and used to prepare Re and 99mTc tricar-
bonyl complexes (Re1, Tc1, Re2, Tc2). The interaction of all these
compounds with CT-DNA was studied using different spectro-
scopic techniques. Based on UV-visible and ﬂuorescence spec-
troscopy, as well as on circular and linear dichroism it was found
thatL1 andRe1 act asDNA intercalators, whileL2 andRe2 have a
much lower afﬁnity towards theDNAdouble helix.Using different
mathematical and computational models the results obtained
on UV-visible and ﬂuorescence were used to calculate intrinsic
binding constants. For L2 and Re2 no model could be adjusted,
certainly due to the poor interaction of these compounds with
DNA. Using the McGhee von Hippel model, the K and n values
obtained forL1 comparewell with the ones reported previously for
acridine orange, but the values found for Re1 must be taken with
caution, mainly due to the high value found for the binding size
site (n = 17.8, Re1), which may reﬂect the larger net positive charge
of Re1 (+2). Based on the ﬂuorescence emission of the AO and on
the possibility of preparing analogous Re and Tc tricarbonyl com-
plexes, it was found that Re1 and 99mTc1 internalize signiﬁcantly
and are retained in the nucleus of B16F1 murine melanoma cells.
Studies with plasmid DNA also conﬁrm that Tc1 induces reduc-
tion of the sc band intensity, reﬂecting the expected high afﬁnity of
the complex to DNA, its ability to intercalate and the emission of
Auger electrons. The absence of DSBs may indicate that a linker
shorter than the butylenic one has to be explored in our studies, to
assure a closer proximity of the radiometal to theDNA.The results
presented herein, together with the stability and versatility of this
type of complexes, encourage the synthesis of 99mTc trifunctional
complexes for cell-speciﬁc and DNA targeting, as well as the
evaluation of their therapeutic effect as Auger-emitters.
Experimental section
Chemistry
All chemicals were of reagent grade. Solvents were dried and
distilled prior to use according to described procedures.25 Unless
stated otherwise, the syntheses of the ligands and complexes were
carried under a nitrogen atmosphere, using standard Schlenk
techniques and dry solvents; the work-up procedures were
performed under air. Compounds 2-(4-bromobutyl)isoindoline-
1,3-dione,26 and tert-butyl N-(2-{[(tert-butoxy)carbonyl](2-{4-
[2-(2,5-dioxopyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethylpyrazol-1-
yl}ethyl)amino}ethyl)carbamate (3)14 were prepared according to
This journal is © The Royal Society of Chemistry 2010 Org. Biomol. Chem., 2010, 8, 4104–4116 | 4111
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published methods. The starting material fac-[Re(H2O)3(CO)3]Br
was synthesized by the literature method.27
Na[99mTcO4] was eluted from a commercial 99Mo/99mTc gener-
ator, using 0.9% saline. 1H and 13C NMR spectra were recorded
on a Varian Unity 300 MHz spectrometer; 1H and 13C chemical
shifts are given in ppm and were referenced to the residual solvent
resonances relative to SiMe4. The NMR samples were prepared
in CDCl3 or CD3OD. J values are given in Hz. IR spectra
were recorded in the range 4000–200 cm-1 as KBr pellets on
a Bruker Tensor 27 spectrometer. Electrospray ionisation mass
spectrometry (ESI-MS) was performed using a Bruker HCT
electrospray ionization quadrupole ion trap mass spectrometer.
Elemental analyses were performed on a Perkin-Elmer automatic
analyser.
Thin layer chromatography (TLC) was done on Merck silica gel
60F254plates.Columnchromatographywasperformedwith silica
gel 60 (Merck). HPLC analysis of the ligands, Re complexes and
99mTc complexes was performed on a Perkin-Elmer LC pump 200
coupled to a LC 290 tunable UV–vis detector and to a Berthold
LB-507A radiometric detector, using an analytic Macherey-Nagel
C18 reversed-phase column Nucleosil 100-5, 250 ¥ 4 mm, with
a ﬂow rate of 0.9 mL min-1; UV detection, 254 nm; eluents,
A: aqueous 0.1% CF3CO2H solution, B: acetonitrile; method:
0–3 min, 100% A; 3–3.1 min, 100%–75% A; 3.1–9 min, 75%
A; 9–9.1 min 75%–66% A; 9.1–18 min, 66%–0% A; 18–25 min,
0% A; 25–25.1 min, 0%–100% A; 25.1–30 min, 100% A. HPLC
puriﬁcation of the radioactive compound was done with a semi-
preparative Macherey-Nagel EP 250 ¥ 8 Nucleosil 100-7 C18
reversed-phase column at a ﬂow rate of 2.0 mL min-1 using
the same methodology as for analytical HPLC. Radioactivity
measurements were done using a ionization chamber Aloka,
Curiemeter IGC-3 or a g-counter Berthold, LB 2111.
Synthesis of the bifunctional ligands L1 and L2
10-(4-Amino-butyl)-3,6-bis-dimethylamino-acridinium (1). p-
Xylol (90 cm3) was added to acridine orange (1 g, 3.769 mmol)
and 2-(4-bromobutyl)isoindoline-1,3-dione (3.2 g, 11.306 mmol)
and reﬂuxed overnight. The reaction mixture was ﬁltered and the
solid obtained was washed with acetone, dried under reduced
pressure and puriﬁed by column chromatography (eluent: CH2Cl2
(98–80%)/MeOH (2–20%)) giving 3,6-bis(dimethylamino)-10-(4-
(1,3-dioxoisoindolin-2-yl)butyl)acridinium (0.597 g, 31%) as a
red–orange solid. dH(300 MHz; CDCl3; Me4Si) 1.90 (2H, m,
CH2), 2.06 (2H, t, J 6.6, CH2), 3.25 (12H, s, 4CH3), 3.80 (2H,
t, J 6.6, CH2), 4.88 (2H, m, CH2), 6.51 (2H, s, 2CH-Ar), 6.94
(2H, d, J 8.7, 2CH-Ar), 7.68 (2H, m, 2CH-Ar), 7.74 (2H,
m, 2CH-Ar), 7.81 (2H, d, J 8.7, 2CH-Ar), 8.63 (1H, s, CH-
Ar). Hydrazine hydrate (0.471 g, 9.416 mmol) was added to a
suspension of 3,6-bis(dimethylamino)-10-(4-(1,3-dioxoisoindolin-
2-yl)butyl)acridinium in a mixture of methanol and ethanol (3 : 1)
and reﬂuxed overnight. After addition of 4 cm3 of concentrated
HCl (37%) a white solid of phthalic acid hydrazide precipitated.
After ﬁltration the pH of the solution was adjusted to about 9 with
3 M NaOH. The reaction mixture was extracted with chloroform
(3 ¥ 50 cm3) and the combined organic phases were dried over
MgSO4 and evaporated under reduced pressure to give 1 (0.450 g,
95%) as a red–orange solid. dH(300 MHz; CD3OD; Me4Si) 1.95
(2H, m, CH2), 2.08 (2H, m, CH2), 3.01 (2H, t, J 6.9, CH2), 3.33
(12H, s, 4CH3), 4.78 (2H, t, J 8.1, CH2), 6.68 (2H, d, J 2.1, 2CH-
Ar), 7.26 (2H, dd, J 2.1, J 2.4 and J 9.0, 2CH-Ar), 7.90 (2H,
d, J 9.3, 2CH-Ar), 8.66 (1H, s, CH-Ar); dC(75.4 MHz; CD3OD;
Me4Si) 24.42 (CH2), 26.40 (CH2), 40.57 (CH2), 40.95 (4CH3), 47.69
(CH2), 93.61 (2CH-Ar), 115.43 (2CH-Ar), 118.38 (2C-Ar), 134.38
(2CH-Ar), 143.95 (2C-Ar), 144.30 (CH-Ar), 157.32 (2C-Ar).
N-(4-Aminobutyl)acridine-9-carboxamide (2). After being
stirred for two hours at room temperature, a suspension
of 9-acridine carboxylic acid (0.460 g, 2.061 mmol) and
benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hex-
aﬂuorophosphate (BOP) (1 g, 2.261 mmol) in 25 cm3 of CH2Cl2,
was cooled to 0 ◦C and 1,4-diamino butane (1 cm3, 10.275
mmol) was added drop by drop. The reaction mixture was stirred
again for 2 days at room temperature. The solvent was removed
and the residue was puriﬁed by column chromatography (eluent:
CHCl3 (95–0%)/MeOH (5-80%)/NH4OH 25% (0–20%)) to give
5 (0.415 g, 69%) as a yellow solid. dH(300 MHz; CD3OD; Me4Si)
1.79 (4H, m, 2CH2), 2.85 (2H, t, J 6.9, CH2), 3.65 (2H, t, J 6.3,
CH2), 7.67 (2H,m, 2CH-Ar), 7.87 (2H,m, 2CH-Ar), 8.06 (2H, d, J
8.7, 2CH-Ar), 8.19 (2H, d, J 9.0, 2CH-Ar); dC(75.4MHz;CD3OD;
Me4Si) 27.72 (CH2), 29.51 (CH2), 40.76 (CH2), 41.51 (CH2), 123.65
(2C-Ar), 126.56 (2CH-Ar), 128.21 (2CH-Ar), 129.56 (2CH-Ar),
132.05 (2CH-Ar), 132.33 (C-Ar), 149.57 (2C-Ar), 169.21 (C O).
10 - (4 - (2 - (1 - (2 - tert -Butoxycarbonyl(2 - (tert - butoxycarbonyl-
amino)ethyl)amino)ethyl)-3,5-dimethylpyrazol-4-yl)acetamido)-
butyl)-3,6-bis(dimethylamino)acridinium (4). To a solution of
1 (0.045 g, 0,107 mmol) in dry DMF (20 cm3) kept stirring
for one hour at room temperature, was added a solution of
3 (0.055 g, 0.102 mmol) and DIPEA (19 ml, 0.107 mmol) in
DMF (15 cm3). After ﬁve days the solvent was removed under
reduced pressure and the dry residue obtained was puriﬁed by
column chromatography (eluent: CHCl3 (95–60%)/MeOH (5–
35%)/NH4OH 25% (0–5%)) to give 4 (0.054 g, 63%) as a dark
orange solid. dH(300 MHz; CDCl3; Me4Si) 1.35 (18H, m, 6CH3
(BOC)), 1.95 (4H, m, 2CH2), 2.07 (6H, m, 2CH3), 3.05 (4H, m,
2CH2), 3.31 (18H, m, 3CH2, 4CH3), 3.99 (2H, m, CH2), 4.70
(2H, m, CH2), 5.27 (1H, s br, NH), 5.73 (1H, s, br, NH), 6.57
(2H, s, 2CH-Ar), 6.97 (2H, d, J 9.0, 2CH-Ar), 7.75 (2H, t, J 8.7
and J 9.0, 2CH-Ar), 8.47 (1H, d, J 15.9, CH-Ar); dC(75.4 MHz;
CDCl3;Me4Si) 9.14 (CH3), 11.37 (CH3), 17.95 (CH2), 25.03 (CH2),
27.77 (3CH3, BOC), 30.74 (CH2), 38.91 (CH2), 40.46 (4CH3), 41.68
(CH2), 47.45 (CH2), 53.23 (2CH2), 57.13 (CH2), 78.42 (C-BOC),
79.31 (C-BOC), 92.13 (2CH-Ar), 109.89 (C4-pz), 113.55 (2CH-Ar),
116.52 (2C-Ar), 132.86 (2CH-Ar), 137.48 (C3/5-pz), 142.05 (2C-Ar),
146.11 (C3/5-pz), 155.08 (2CH-Ar), 155.60 (2C O, BOC), 171.29
(C O).
10-(4-(2-(1-(2-(2-Aminoethylamino)ethyl)-3,5-dimethyl-1H-
pyrazol -4-ylacetamido)butyl) -3,6-bis(dimethylamino))acridinium
(L1). 4 (0.244 g, 0.290 mmol) was dissolved in a mixture
of TFA (2 cm3, 25.960 mmol) and CH2Cl2 (1 : 1) and stirred
at room temperature overnight. After that period of time the
solvent was removed under reduced pressure and the solid was
washed with ethyl acetate to give L1(CF3CO2)·3.5TFA (0.258 g,
0.241 mmol, 83%) as a red–orange solid (Found: C, 45.29; H,
5.27; N, 11.04. C34H47F3N8O2·3.5(CF3CO2H) requires C, 45.94;
H, 4.76; N, 10.46%); dH(300 MHz; CD3OD; Me4Si) 1.82 (2H, m,
CH2), 1.98 (2H, m, CH2), 2.03 (3H, s, CH3), 2.15 (3H, s, CH3),
4112 | Org. Biomol. Chem., 2010, 8, 4104–4116 This journal is © The Royal Society of Chemistry 2010
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3.23 (20H, m, 4CH2, 4CH3), 3.50 (2H, t, J 5.7, CH2), 4.31 (2H, t,
J 5.7, CH2), 4.70 (2H, t, J 7.8, CH2), 6.64 (2H, s, 2CH-Ar), 7.24
(2H, dd, J 1.5, J 2.1 and J 9.0, 2CH-Ar), 7.87 (2H, d, J 9.0, 2CH-
Ar), 8.62 (1H, s, CH-Ar); dC(75.4 MHz; CD3OD; Me4Si) 9.37
(CH3), 11.88 (CH3), 24.79 (CH2), 28.27 (CH2), 31.30 (CH2), 36.85
(CH2), 40.21 (CH2), 40.84 (4CH3), 45.06 (CH2), 45.80 (CH2), 93.62
(2CH-Ar), 112.04 (C4-pz), 115.51 (2CH-Ar), 118.12 (CTFA) 118.47
(2C-Ar), 134.37 (2CH-Ar), 140.32 (C3/5-pz), 144.02 (2C-Ar), 144.29
(1CH-Ar), 149.15 (C3/5-pz), 157.35 (2CH-Ar), 163.56 (CTFA), 173.83
(C O); dF(281.98 MHz; CD3OD; Me4Si) -76.39 (CF3CO2H); tR =
14.99 min (100-5 C18, 0.9 mL min-1); m/z (ESI-MS) 559.1 [M]+,
280.0 [M + H]2+.
N -(4-(2-(1-(2-(tert-Butoxycarbonyl)-2-(tert-butoxycarbonyla-
mino)ethyl)amino)ethyl)-3,5-dimethyl-1H-pyrazol-4-ylacetamido)-
butyl)acridine-9-carboxamide (5). A solution of 3 (0.516 mmol)
and DIPEA (0.151 g, 0.516 mmol) in dry DMF (10 cm3) was
added to a solution of 2 (0.264 g, 0.491 mmol) in DMF (30 cm3)
and stirred for 5 days at room temperature. The solvent was then
removed and the residue was puriﬁed by column chromatography
(eluent: CHCl3 (90–54%)/MeOH (10–46%)) to give 5 (0.294 g,
84%) as a yellow oil. dH(300 MHz; CDCl3; Me4Si) 1.25 (9H, s,
3CH3 (BOC)), 1.37 (9H, s, 3CH3 (BOC)), 1.58 (2H, m, CH2),
1.68 (2H, m, CH2), 1.98 (3H, s, CH3), 2.00 (3H, s, CH3), 3.08
(2H, s, CH2), 3.14 (8H, m, 4CH2), 3.38 (1H, NH), 3.55 (2H,
m, CH2), 3.89 (2H, s, CH2), 6.59 (1H, s br, NH, amide), 6.67
(1H, s br, NH, amide), 7.37 (2H, t, J 8.1 and J 6.6, 2CH-Ar),
7.59 (2H, t, J 8.4 and J 6.9, 2CH-Ar), 7.82 (2H, d, J 8.4, 2CH-
Ar), 7.94 (2H, d, J 9.0, 2CH-Ar); dC(75.4 MHz; CDCl3; Me4Si)
9.07 (CH3), 11.17 (CH3), 26.49 (CH2), 26.71 (CH2), 27.77 (6CH3
(BOC)), 28.14 (6CH3 (BOC)), 30.80 (CH2), 36.01 (CH2), 38.43
(CH2), 38.89 (CH2), 39.34 (CH2), 47.17 (CH2), 48.62 (CH2), 78.55
(C-BOC), 79.21 (C-BOC), 109.43 (C4-pz), 121.62 (2C-Ar), 124.97
(2CH-Ar), 126.10 (2CH-Ar), 128.68 (2CH-Ar), 129.91 (2CH-Ar),
137.38 (C-Ar), 141.30 (C3/5-pz), 145.77 (2C-Ar), 147.70 (C3/5-pz),
155.05 (C O, BOC), 155.77 (C O, BOC), 166.59 (C O), 170.75
(C O).
N - (4-(2-(1-(2-(2-Aminoethylamino)ethyl) -3,5-dimethyl-1H-
pyrazol-4-yl)acetamido)butyl)acridine-9-carboxamide (L2). 5
(0.294 g, 0.411 mmol) was dissolved in a mixture of TFA (2 cm3,
25.960 mmol) and CH2Cl2 (1 : 1) and stirred overnight at room
temperature. After that time the solvent was removed under
reduced pressure, the residue was washed with CHCl3 and puriﬁed
by column chromatography (eluent: CHCl3 (95–70%)/MeOH
(5–20%)/NH4OH 25% (0–10%)) to give L2·2TFA (0.184 g,
0.247 mmol, 84%) as a yellow oil. (Found: C, 54.48; H, 5.46; N,
14.42. C29H37N7O2·2(CF3CO2H) requires C, 53.29; H, 5.30; N,
13.19%); dH(300 MHz; CD3OD; Me4Si) 1.70 (4H, m, 2CH2), 2.12
(3H, s, CH3), 2.16 (3H, s, CH3), 2.63 (2H, t, J 6.0, CH2), 2.71
(2H, t, J 5.4, CH2), 2.88 (2H, t, J 6.3, CH2), 3.24 (4H, m, 2CH2),
3.61 (2H, t, J 6.9 and J 7.5, CH2), 4.00 (2H, t, J 5.7 and J 6.6,
CH2), 7.61 (2H, t, J 4.8 and J 6.9, 2CH-Ar), 7.83 (2H, t, J 5.1
and J 6.9, 2CH-Ar), 8.01 (2H, d, J 8.4, 2CH-Ar), 8.13 (2H, d, J
8.7, 2CH-Ar). dC(75.4 MHz; CD3OD; Me4Si) 9.30 (CH3), 11.56
(CH3), 27.90 (CH2), 31.04 (CH2), 36.66 (CH2), 40.04 (CH2), 40.83
(CH2), 44.88 (CH2), 45.64 (CH2), 112.45 (C4-pz), 118.23 (CTFA)
121.44–138.65 (8CH-Ar, 5C-Ar), 140.90 (C3/5-pz), 148.91 (C3/5-pz),
162.94 (CTFA), 173.58 (C O); dF(281.98 MHz; CD3OD; Me4Si)
-75.81 (CF3CO2H); tR: 10.95 min (100-5 C18, 0.9 ml min-1); m/z
(ESI-MS) 516.1 [M + H]+.
General procedure for the synthesis of the Re complexes (Re1–Re2)
[Re(H2O)3(CO)3]Brwas reacted overnightwith equimolar amounts
of L1–L2 in reﬂuxing methanol. After this time, the solvent was
removed under reduced pressure and the desired products were
puriﬁed by column chromatography.
fac-[Re(CO)3(j3-L1)](CF3CO2)2·2TFA. Re1 was obtained by
reﬂux in methanol and puriﬁed by column chromatography
(eluent: CHCl3 (80–37%)/MeOH (20–45%)/NH4OH 25% (0–
18%)) to give a red–orange solid (90 mg, 0.070 mmol, 68%).
(Found: C, 40.77; H, 3.17; N, 9.31. C39H47F6N8O8Re·2(CF3CO2H)
requires C, 40.22; H, 3.85; N, 8.73%); nmax(KBr)/cm-1 (CO) 1890,
2024; dH(300 MHz; CD3OD; Me4Si) 1.84 (2H, m, CH2), 2.04
(2H, m, CH2), 2.25 (3H, s, CH3), 2.32 (3H, s, CH3), 2.54 (3H,
m, 3CH), 2.84 (3H, m, 3CH), 3.33 (12H, s, 4CH3), 3.38 (2H, s,
CH2), 3.52 (1H, m, 1CH), 3.86 (1H, s br, 1NH), 4.09 (1H, t, J 12.3
and J 13.2, 1CH), 4.50 (1H, d, J 15.9, 1CH), 4.77 (2H, t, J 7.2,
CH2), 5.41 (1H, s br, 1NH), 6.71 (2H, s, 2CH-Ar), 6.91 (1H, s br,
1NH), 7.29 (2H, d, J 9.3, 2CH-Ar), 7.93 (2H, d, J 9.3, 2CH-Ar),
8.68 (1H, s, CH-Ar); dC(75.4 MHz; CD3OD; Me4Si) 10.38 (CH3),
14.57 (CH3), 24.89 (CH2), 28.27 (CH2), 31.30 (CH2), 40.95 (4CH3),
43.22 (CH2), 48.72 (3CH2), 55.86 (CH2), 93.62 (2CH-Ar), 113.98
(C4-pz), 115.52 (2CH-Ar), 118.47 (2C-Ar), 134.37 (2CH-Ar), 143.72
(C3/5-pz), 143.97 (CH-Ar), 144.29 (2C-Ar), 153.46 (C3/5-pz), 157.30
(2C-Ar), 162.93 (TFA), 172.91 (C O), 194.14-194.71 (3CO); tR =
17.69 min (100-5 C18, 0.9 ml min-1); m/z (ESI-MS): 414.9 [M]2+.
fac-[Re(CO)3(j3-L2)](CF3CO2)·2TFA. Re2 was obtained by
reﬂux in methanol and the solvent was removed under reduced
pressure to give a yellow solid (49 mg, 0.043 mmol, 89%). (Found:
C, 38.04; H, 2.70; N, 8.83. C34H37F3N7O5Re·2(CF3CO2H) requires
C, 38.36; H, 3.49; N, 8.70%); nmax(KBr)/cm-1 (CO) 1922, 2024;
dH(300 MHz; CD3OD; Me4Si) 1.75 (2H, m CH2), 1.81 (2H, m,
CH2), 2.32 (3H, s, CH3), 2.41 (3H, s, CH3), 2.51 (1H,m, 1CH), 2.62
(1H, m, 1CH), 2.81 (3H, m, 3CH), 3.43 (3H, m, CH, CH2), 3.67
(2H, m, CH2), 3.90 (1H, s br, NH), 4.08 (1H, t, J 12.6 and J 13.2,
1CH), 4.50 (1H, d, J 15.6, 1CH), 5.39 (1H, s br,NH), 6.88 (1H, s br,
NH), 7.78 (2H, t, J 8.1 and J 6.9, 2CH-Ar), 8.05 (2H, t, J 6.9 and
J 7.8, 2CH-Ar), 8.14 (2H, m, 2CH-Ar), 8.26 (2H, d, J 8.7, 2CH-
Ar); dC(75.4 MHz; CD3OD; Me4Si) 10.45 (CH3), 14.58 (CH3),
27.83 (CH2), 28.04 (CH2), 31.34 (CH2), 40.25 (CH2), 40.89 (CH2),
43.26 (CH2), 55.86 (CH2), 114.16 (C4-pz), 118.00 (CTFA), 123.78 (2C-
Ar), 126.62 (2C-Ar), 127.18 (2CH-Ar), 129.00 (2CH-Ar), 134.77
(2CH-Ar), 143.75 (C3/5-pz), 146.77 (2C-Ar), 147.63 (C-Ar), 153.52
(C3/5-pz), 162.50 (CTFA), 167.96 (C O), 172.89 (C O), 194.14-194,63
(3CO); dF(281.98 MHz; CD3OD; Me4Si) -75.87 (CF3CO2H); tR =
15.06 min (100-5 C18, 0.9 ml min-1); m/z (ESI-MS): 786.0 [M]+,
393.4 [M+ + H]2+.
General procedure for the synthesis of the 99mTc complexes
(Tc1–Tc2)
In a glass vial, 100 ml of a 10-4 M aqueous solution of L1–
L2 were added to 900 ml of the organometallic precursor fac-
[99mTc(CO)3(H2O)3]+ (1–2 mCi) in saline at pH 7.4. The reaction
This journal is © The Royal Society of Chemistry 2010 Org. Biomol. Chem., 2010, 8, 4104–4116 | 4113
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mixture was heated to 100 ◦C for 30 to 40 min, cooled at room
temperature and the ﬁnal solution analyzed by RP-HPLC.
Partition coefﬁcient measurements
The log Po/w values of complexes Tc1–Tc2 (Table 1) were deter-
mined by the “shake ﬂask”method under physiological conditions
(n-octanol/0.1MPBS, pH 7.4).16 TheHPLC-puriﬁed compounds
(100 ml, ~100mCi) were added to a test tube containing 1 ml of n-
octanol and 1 ml of the PBS solution. The tube was vortexed for
1 min and centrifuged for 5 min at 3500 rpm. After centrifugation,
500 ml of the organic phase were transferred to another tube and
further extracted with 500 ml of the PBS solution, as described for
the ﬁrst extraction.After separation of the phases, 50ml aliquots of
eachphasewere taken for radioactivitymeasurement (in duplicate)
using a g-counter. The partition coefﬁcient (Po/w) was calculated
based on the ratio (activity in octanol layer)/(activity in aqueous
layer) and is expressed as log Po/w.
DNA binding studies
Calf thymus DNA (CT-DNA) sodium salt was purchased from
Sigma and was used without further puriﬁcation. The DNA con-
centrations per nucleotide of stock solutions in Tris buffer (Tris-
HCl 0.1M, pH 7.4) were determined by absorption spectroscopy
at 260 nm, after adequate dilution with the buffer and using the
reported molar absorptivity of 6600 M-1 cm-1.28 The purity of the
DNAsampleswas checked bymonitoring the valueA260/A280 ratio.
All measurements that involved DNA and the different tested
compounds (L1, L2, Re1 and Re2) were carried out in Tris buffer
(Tris-HCl 0.1M, pH 7.4) or in phosphate buffer (10 mM, pH 7.2).
The absorption and ﬂuorescence titrations were performed by
keeping the concentrations of the probe constant, while varying
the concentrations of the DNA. To obtain the intrinsic binding
constant (K) all calculations were done by considering the DNA
concentration in base pairs, and the datawere corrected for volume
changes.
Absorption spectroscopy studies
UV-Vis absorption spectra were recorded on a Hitachi U-2000
spectrophotometer by using 1 cmpath-length quartz cells. In order
to eliminate any interference of the DNA absorbance in the region
of absorbance of the acridine derivative chromophores an equal
amount of CT-DNA in Tris buffer was added to the sample and
reference cells. After each addition of CT-DNA, the solution was
allowed to equilibrate and the absorption spectrum was recorded
until there were no further changes in the absorbance.
According to the Scatchard model29 the absorption titration
data were ﬁtted to eqn (1) where D is the concentration of DNA
in base pairs and Deap = [ea - eF] and De = [eB - eF].
D/Deap = D/De + 1/DeK (1)
The apparent extinction coefﬁcient, ea, is the ratio of the
observed absorbance of the sample and the total concentration
of the probe (Aobs/[probe]). eB and eF correspond to the extinction
coefﬁcients of the bound and free forms of the probe, respectively.
The intrinsic binding constant (K) was determined from the plot
of D/Deap vs. D.
According to theKaminohmodel30 the absorption titrationdata
were ﬁtted to eqn (2).
A = (A0 + K[DNA]Asat)/(1 + K[DNA]) (2)
As the concentration of the chromophore and its absorbance in
solution (A0) are known, the value in saturation, Asat, is calculated
from the representation of A vs. [DNA].
Fluorescence spectroscopy studies
Fluorescence spectra were recorded in a Perkin-Elmer LS50B
spectroﬂuorimeter using a quartz cuvette of 1 cm. After each
addition of CT-DNA in Tris buffer, the solution was allowed to
equilibrate and the absorption at the excitation wavelength was
recorded. The ﬂuorescence spectra were then recorded until there
were no further changes in the ﬂuorescence intensity. Compounds
L1 and Re1 were excited at 470 nm, while compounds L2 and Re2
were excited at 359 nm. Emission and excitation slits were chosen
in order to maximize the ﬂuorescence intensity. Emission spectra
were recorded from l = 400–700 nm for compounds L1 and Re1,
and from l = 350–650 nm for compounds L2 and Re2, with a scan
speed of 150 nm min-1. The ﬂuorescence data were also used to
determine the intrinsic binding constant (K) of the probes.
According to the Scatchard model29 the data were ﬁtted to eqn
(3) where D is the concentration of DNA in base pairs and DI ap =
[I ap - IF] and DI = [IB - IF].
D/DI ap = D/DI + 1/DIK (3)
The apparent emission intensity, I a, is the ratio of the observed
intensity of the sample and the total concentration of the probe
(Iobs/[probe]). IB and IF correspond to the emission intensities of
the bound and free forms of the probe, respectively. The intrinsic
binding constant (K) was determined from the plot of D/DI ap vs.
D.
According to the Kaminoh model30 the data were ﬁtted to eqn
(4).
I = (I 0 + K[DNA]I sat)/(1 + K[DNA]) (4)
As the concentration of the chromophore and its emission
intensity (I 0) are known, the value in saturation, I sat, is calculated
from the representation of I vs. [DNA].
According to theMcGhee vonHippelmodel31 the concentration
of the free probe in each sample (CF) was calculated using eqn (5),
where CT is the total concentration of the probe and P is the ratio
of the observed ﬂuorescence intensity of the bound probe to that
of the free probe.
CF = CT(I/I 0 - P)/(1 - P) (5)
The value of P is the y-intercept from the plot of I/I 0 vs.
1/[DNA], I and I 0 are the ﬂuorescence intensities of the probes in
the presence or absence ofDNA.The amount of bound probe (CB)
at any concentration is given by CT - CF. The binding constant
(K) and the binding site size (n) in base pairs were obtained from
the plot of r/CF vs. r, where r = CB/[DNA] using eqn (6).
r/CF = K(1 - nr)[(1 - nr)/[1 - (n - 1)r]]n - 1 (6)
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Circular dichroism (CD) studies
The CD spectra were recorded at 24 ◦C on a Jasco J-720
spectropolarimeter with UV/Vis (200–700 nm) photomultiplier.
Solutions of the probe and CT-DNA in Tris buffer were placed
in a 1 cm (or 2 cm) path-length quartz cell, and the spectra
were recorded in the 200–650 nm region with subtraction of the
buffer baseline. The following operating parameters were used to
collect the CD spectra: bandwidth, 0.5 nm; sensitivity, 10 mdeg;
resolution, 0.2 nm; scan speed, 50 nm min-1; response time 4 s;
accumulations, 3.
Linear dichroism (LD) studies
The LD measurements were performed with a Jasco J500 A
spectropolarimeter that was equipped with an IBM PC and a
Jasco J interface. The studies were done with CT-DNA in 10 mM
phosphate buffer at pH 7.2, and the sample orientation was
produced by a device that was designed by Wada and Kozawa
for the studies of differential ﬂow dichroism of polymer solutions
at a shear gradient of 700 rpm.32 The reduced linear dichroism,
was deﬁned by the ratio (LDr = LD/Aiso) between the LD values
and the absorbance of the unoriented sample at rest (Aiso), which
might be related to the orientation of DNA and the angle between
the respective light-absorbing transition moment and DNA helix
axis according to Norden et al.33
Cell studies
Cell culture. B16F1 murine melanoma cells (ECACC, UK)
were grown in DMEM containing GlutaMax I supplemented
with 10% heat-inactivated fetal bovine serum and 1% peni-
cillin/streptomycin antibiotic solution (all from Invitrogen). Cells
were cultured in a humidiﬁed atmosphere of 95% air and 5% CO2
at 37 ◦C (Heraeus, Germany), with the medium changed every
other day.
Fluorescence microscopy
B16F1 murine melanoma cells were cultured overnight on sterile
coverslips, at ~5 ¥ 104 cells per well. The next day the medium was
discarded and replaced by fresh medium containing the ligands
(L1 or L2) or complexes (Re1 or Re2) (70 mM) and cells were incu-
bated for 3 h. After this loading, cells were washed with PBS and
ﬁxed for 20min at room temperaturewith 3%paraformaldehyde in
PBS. After 3 washings with PBS, cells on the coverslips were incu-
bated in 5 mM DAPI (4¢-6-diamidino-2-phenylindol) (for L1 and
Re1) or 5 mM DRAQ5 (1,5-bis{[2-(dimethylamino)ethyl]amino}-
4,8-dihydroxyanthracene-9,10-dione) (for L2 and Re2) for nuclear
staining for 20 min at room temperature. After 3 more washings
in PBS, the coverslips were mounted on standard microscope
slides with glycerol + 3% N-propyl gallate to improve the optical
conditions and to prevent photobleaching. The samples were then
imaged on a Leica DMRA2 upright microscope using a 100¥
1.2NA objective and a Chroma +A4 UV ﬁlter for evaluating the
ﬂuorescence of DAPI (lex max= 359 nm, lem max= 461 nm) and
L2 and Re2, a Y5 Cy5 ﬁlter for DRAQ5 (lex max= 647 nm, lem
max= 670 nm) and a L5 FITC ﬁlter for L1 and Re1. Images were
acquired and colour-combined by using a CoolSNAP HQ 1.3
Mpixel-cooled CCD camera and the MetaMorph software.
Confocal ﬂuorescence microscopy
B16F1 murine melanoma cells were prepared as described above
and incubated with L1 and Re1 (70 mM) and 5 mM DAPI
solution for nuclear staining. After washing, the coverslips were
mounted on standard microscope slides. The samples were then
imaged on a Zeiss LSM 510 META inverted laser scanning
confocal microscope using a 63¥/1.4 Apochromat objective. The
ﬂuorescence of L1 and Re1 was detected using the 488 nm laser
line of an Argon/2 laser and a BP 505-550 emission ﬁlter. DAPI
ﬂuorescence was detected using a 405 nm Diode laser and a BP
420-480 emission ﬁlter.
Cellular internalization and retention
The cellular internalization assay was performed in B16F1murine
melanoma cells seeded at a density of 2 ¥ 105 cells per well in 24-
well tissue culture plates and allowed to attach overnight. The cells
were incubated at 37 ◦C for a period of 5 min to 24 h with about
200 000 cpm of the complex in 0.5 mL of assay medium [MEM
with 25mMN-(2-hydroxyethyl)piperazine-N¢-ethanesulfonic acid
and 0.2% BSA]. Incubation was terminated by washing the cells
with ice-cold assay medium. Cell-surface-bound radioligand was
removed by two steps of acid wash (50 mM glycine·HCl/100 mM
NaCl, pH 2.8) at room temperature for 5 min. pH was neutralized
with cold PBS with 0.2% BSA and, subsequently, the cells were
lysed by a 10 min incubation with 1 N NaOH at 37 ◦C to
determine the internalized radioligand. The cellular retention of
the internalized radioconjugate was determined by incubating
cells with the radiolabeled compound for 3 h at 37 ◦C, washing
them with cold assay medium, removing the membrane-bound
radioactivity with acid buffer wash and monitoring radioactivity
release into the culture media (0.5 ml) at 37 ◦C. At different
time points over a 4 h incubation period, the radioactivity in the
medium and in the cells were separately collected and counted in
a g-counter. Cellular internalization and retention data was based
on three determinations for each time point, and are expressed as
an average plus the standard deviation.
Nuclear internalization
B16F1 cells were seeded at a density of 0.2 million/well into 24-
well tissue culture plates and allowed to attach overnight. Cells
were incubated in humidiﬁed 5% CO2/95% air, 37 ◦C for a period
of 30 min, 1, 2, 3, 4, 5 and 6 h with about 200 000 cpm of
radioconjugate in 0.5 mL of assay medium. After incubation cells
were washed with PBS with 0.2% BSA (250ml/well) and removed
from the plate with trypsin (100 ml/well). The inactivation of
trypsin was performed with 250 ml of culture medium. The cells in
suspension were centrifuged (800 rpm, 2 min) and washed twice
with cold PBS with 0.2% BSA. Cells were lysed in 500 ml of lysis
buffer (Tris 10 mM, MgCl2 1.5 mM, NaCl 140 mM, Nonidet P-
40 0.02%, pH 8.0–8.3). After 15 min of incubation in ice, the
cell suspension was centrifuged at 1300 g at 4 ◦C for 1 min.
The activities of supernatant (activity outside the nucleus) and
of the precipitate (activity retained in the nucleus) were measured
(3 replicates) in a g-counter for different incubation times.
This journal is © The Royal Society of Chemistry 2010 Org. Biomol. Chem., 2010, 8, 4104–4116 | 4115
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Plasmid DNA studies
DNA cleavage activity was evaluated by monitoring the conver-
sion of supercoiled plasmid DNA (sc) to open circular DNA (oc)
or linear DNA. Plasmid DNA (300 ng, pUC19) was incubated
with complexes Re1 and Tc1 for 48 h at room temperature
in Tris (pH = 7.4). After this time, 5 mL of DNA loading
buffer was added and the samples were loaded onto a 0.8%
agarose gel (AppliChem) in TBE 1¥ (Tris-borate-EDTA) buffer
containing 15 mL of ethidium bromide (10 mg mL-1, AppliChem)
for visualization of DNA. Controls of non-incubated and of
linearized plasmid were included in both extremes of an 18-well
gel plate. The electrophoresis was carried out for 18 h at 20
mV. Bands were visualised under UV light and photographed
using an AlphaImager EP (Alpha Innotech). All samples in the
ﬁgure were obtained from the same run. Peak areas weremeasured
by densiometry using AlphaView Software from Alpha Innotech.
Peak areas for the sc form were corrected using the factor 1.42 to
account for its lower staining capacity by ethidium bromide34 and
used to calculate the percentage of each form (sc and oc), and the
ratio sc/oc.
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